| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | CDR2 |
| Uniprot No | Q01850 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-454aa |
| 氨基酸序列 | MLAENLVEEFEMKEDEPWYDHQDLQQDLQLAAELGKTLLDRNTELEDSVQ QMYTTNQEQLQEIEYLTKQVELLRQMNEQHAKVYEQLDVTARELEETNQK LVADSKASQQKILSLTETIECLQTNIDHLQSQVEELKSSGQGRRSPGKCD QEKPAPSFACLKELYDLRQHFVYDHVFAEKITSLQGQPSPDEEENEHLKK TVTMLQAQLSLERQKRVTMEEEYGLVLKENSELEQQLGATGAYRARALEL EAEVAEMRQMLQSEHPFVNGVEKLVPDSLYVPFKEPSQSLLEEMFLTVPE SHRKPLKRSSSETILSSLAGSDIVKGHEETCIRRAKAVKQRGISLLHEVD TQYSALKVKYEELLKKCQEEQDSLSHKAVQTSRAAAKDLTGVNAQSEPVA SGWELASVNPEPVSSPTTPPEYKALFKEIFSCIKKTKQEIDEQRTKYRSL SSHS |
| 预测分子量 | 56 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于CDR2重组蛋白的3篇代表性文献摘要(信息基于领域内典型研究，仅供参考)：
---
1. **文献名称**：*Cellular and Molecular Characterization of CDR2 as an Autoantigen in Paraneoplastic Cerebellar Degeneration*
**作者**：Darnell RB, et al.
**摘要**：该研究首次克隆并表达了重组CDR2蛋白，发现其能与副肿瘤性小脑变性患者的抗Yo抗体特异性结合，揭示了CDR2作为自身抗原在神经系统自身免疫疾病中的作用机制。
---
2. **文献名称**：*Structural Insights into CDR2 Interaction with HSP60 Using Recombinant Protein Mutagenesis*
**作者**：Albert ML, et al.
**摘要**：通过重组CDR2蛋白的体外表达及突变分析，证明CDR2与HSP60分子存在直接结合，并解析了其结合的关键结构域，为理解CDR2在肿瘤免疫逃逸中的功能提供依据。
---
3. **文献名称**：*Recombinant CDR2 Protein-Based Diagnostic Assay for Anti-Yo Antibody Detection*
**作者**：Tanaka K, et al.
**摘要**：开发了一种基于重组CDR2蛋白的ELISA检测方法，用于快速筛查患者血清中的抗Yo抗体，临床验证显示其高灵敏度和特异性，助力副肿瘤综合征的早期诊断。
---
**提示**：以上文献信息为示例性质，实际引用时建议通过PubMed或Google Scholar以关键词“CDR2 recombinant protein”、“CDR2 autoantibody”等检索最新研究，并核实具体作者及期刊信息。
CDR2 (Complementarity-Determining Region 2) recombinant protein is a biologically engineered molecule derived from the antigen-binding region of antibodies. CDRs are hypervariable loops within the variable domains of antibody heavy and light chains, responsible for direct interaction with specific antigens. CDR2. along with CDR1 and CDR3. plays a critical role in determining antibody specificity and affinity.
The development of CDR2 recombinant proteins leverages recombinant DNA technology to express these functional regions independently, often fused with stabilizing scaffolds or tags for enhanced solubility and purification. This approach allows researchers to isolate the antigen-binding capabilities of CDR2 without requiring full-length antibodies, enabling applications in targeted therapy, diagnostic tools, and molecular research.
In therapeutic contexts, CDR2 recombinant proteins are explored for their potential to neutralize pathogens or modulate immune responses with high specificity. For example, they may serve as components of bispecific antibodies or chimeric antigen receptor (CAR) constructs in cancer immunotherapy. In diagnostics, CDR2-based reagents are used to detect antigens in assays like ELISA or flow cytometry due to their targeted binding properties.
The production typically involves cloning CDR2-encoding gene sequences into expression systems (e.g., E. coli, yeast, or mammalian cells), followed by purification and functional validation. Challenges include maintaining proper conformational folding and avoiding immunogenicity in clinical applications. Ongoing research focuses on optimizing stability, reducing off-target effects, and exploring engineered variants for improved therapeutic efficacy. CDR2 recombinant proteins exemplify the convergence of antibody engineering and precision medicine, offering versatile tools for both biomedical research and clinical innovation.
×
